Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
80 participants
INTERVENTIONAL
2008-09-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
NCT00103272
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
NCT00410423
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
NCT00428545
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00818649
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
NCT00111813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Temsirolimus is designed to block pathways that control important events such as the growth of blood vessels that are vital for the growth of cancer. This may cause cancer cells to die.
Topotecan hydrochloride is designed to block the function of important proteins in cancer cells. These proteins, when active, allow a cell's genes to duplicate and for the cancer cells to divide.
Bortezomib is designed to block the function of important proteins in cancer cells. These proteins control the destruction of proteins in tumor cells, which is important for their growth. This may cause cancer cells to die.
Study Drug Dose Level:
If you are found to be eligible to take part in this study, you will be enrolled into a group of about 3-6 participants that are receiving the same drug combination. The first group of participants will receive the lowest dose of the drug combination. The next group of participants will receive the next highest dose of the drug combination. The third group will receive an even higher dose than that. This process will continue until the study doctor finds the highest safe dose of the drug combination. The dose that you receive will depend on when you are enrolled in this study and the safety data that is available at that time. The dose that you receive may be lowered if you do not tolerate the study drug combination well. You will not receive any doses of the study drug higher than the dose you are first assigned to.
Once the highest tolerated dose is found, up to 10 more participants will be added at that dose level. This is called an Expansion Group.
Study Drug Administration:
Temsirolimus, topotecan, and bortezomib will be given in "cycles." Cycles will be about 21 days long or longer, depending on any side effects you may experience.
On Days 1, 8, and 15 of each cycle, you will receive temsirolimus through a needle in your vein over about 30-60 minutes.
On Days 1 and 8 of each cycle, you will receive topotecan hydrochloride by vein over about 30-60 minutes.
On Days 1, 4, 8, and 11 of each cycle, you will receive bortezomib by vein over less than 1 minute.
While on study you will not be able to take any drugs that may interfere with the study drugs. You should talk with your doctor before taking any non-study drugs.
Study Visits:
Once a week during Cycle 1, the following tests and procedures will be performed:
* You will have a physical exam.
* Blood (about 1 tablespoon) will be drawn for routine tests.
* If the doctor thinks it is needed, urine will be collected for routine tests.
If you are in the Expansion Group, then during Week 3 of Cycle 1, you will have a tumor biopsy to compare the activity of the tumor before treatment and after treatment has begun. This is done for research purposes only.
If you are in the Expansion Group, then 24-48 hours after starting Week 1 of Cycle 1, you will have a bone marrow aspiration performed. The tissue will be used to see how the study drug combination acts in the body and to learn the effect it may have on cancer cells. This is done for research purposes only.
During Week 1 of Cycle 2, you will have an ECG. After this, you will have extra ECGs if the doctor thinks it is needed.
During Week 1 of Cycles 2 and beyond, the following tests and procedures will be performed:
* You will have a physical exam.
* Blood (about 1 tablespoon) will be drawn for routine tests.
* If the doctor thinks it is needed, urine may be collected for routine tests.
Once every 2 cycles (Cycles 2, 4, 6, and so on), you will have a CT or MRI scan to check the status of the disease.
FDG-PET Scans:
Every 2-3 months while you are on study and before Cycle 1 if you have not had a FDG-PET within the last 1 month, you may have a FDG-PET scan. You must fast for at least 6 hours before the FDG-PET scan. If you are a diabetic, you must fast for at least 4 hours before the FDG-PET scan. If it is needed, you may take drugs or drink water. The FDG-PET will be used to see if the activity of the cancers decreased with the drugs.
You will receive a small amount of FDG solution by vein. You will then rest in a quiet darkened room for 45-60 minutes before the PET scan. Pictures of your body will be taken using a PET scanner, which will about take 1 1/2 hours. The entire procedure should take about 3 hours.
Each time you have a FDG-PET scan, blood (either a finger stick or about 1 teaspoon) will be drawn to measure your blood sugar levels.
Length of Study Participation:
You will be on study for as long as you are benefiting. You will be taken off study if the disease gets worse or intolerable side effects occur.
End-of-Treatment Visit:
After you are off study, you will have an end-of-treatment visit. At this visit, the following tests and procedures will be performed:
* You will have a physical exam.
* Blood (about 2 teaspoons) will be drawn for routine tests.
This is an investigational study. Temsirolimus, topotecan, and bortezomib are all FDA approved and commercially available. Temsirolimus is FDA approved for the treatment of renal cell cancer. Topotecan hydrochloride is FDA approved for the treatment of ovarian, small cell lung, and cervical cancers. Bortezomib is FDA approved for the treatment of multiple myeloma and mantle cell lymphoma. The use of these drugs together is investigational and authorized for use in research only.
Up to 80 patients will take part in this study. All will be enrolled at M. D. Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Torisel + Hycamtin + Velcade
Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.
Hycamtin starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.
Velcade starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle.
Torisel (Temsirolimus)
Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
Hycamtin (Topotecan)
Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
Velcade (Bortezomib)
Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
Expansion Group
Torisel + Hycamtin + Velcade Expansion Group
Addition of 10 participants at highest tolerated dose level
Torisel (Temsirolimus)
Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
Hycamtin (Topotecan)
Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
Velcade (Bortezomib)
Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Torisel (Temsirolimus)
Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
Hycamtin (Topotecan)
Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
Velcade (Bortezomib)
Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients should be at least four weeks or 5 half lives from the last day of chemotherapy, and antibody or other biological therapy, whichever is shorter.
3. Patients should be at least four weeks from the last day of therapeutic radiation.
4. The Eastern Cooperative Oncology Group (ECOG) performance status \</= 2 or Karnofsky \>/= 60%.
5. Patients must have allowable organ and marrow function defined as: Absolute neutrophil count \>/= 1,000/mL, Platelets \>/=75,000/mL, Serum creatinine \</= 2 \* Upper Limit of Normal (ULN), Total bilirubin \</= 2 \* ULN, aminotransferase (ALT or SGPT) \</= 3 \* ULN, Fasting total cholesterol \<= 350 mg/dL and triglyceride level \<= 400 mg/dL.
6. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and will be advised to avoid pregnancy for 3 months after completion of therapy.
7. Ability to understand and the willingness to sign a written informed consent document.
8. Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except for continuing on hormonal therapy in cases of prostate cancer.
9. Treatment on this study may begin within 24 hours after Phase 0 dose of temsirolimus.
Exclusion Criteria
2. Patients with clinically significant unexplained bleeding within 28 days prior to entering the study.
3. Patients with clinically significant cardiovascular disease: • History of CVA within 6 months • Myocardial infarction or unstable angina within 6 months • Unstable angina pectoris
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics on Day 1.
5. Pregnant or lactating women.
6. History of hypersensitivity to bortezomib or any component of the bortezomib formulation.
7. History of hypersensitivity to topotecan or any component of the topotecan formulation.
8. History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Karp, MD
Role: PRINCIPAL_INVESTIGATOR
UT MD Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
UT MD Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-0425
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.